Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Lung Cancer Clinical Trial

Official title: Use Of Proteomic Analysis Of Serum Samples For Detection Of Non-Small Cell Lung Cancer

Status Completed

Clinical Trial Summary

RATIONALE: Evaluating specific proteins in the blood may be an effective and noninvasive procedure to help doctors determine if a patient has early non-small cell lung cancer.

PURPOSE: This clinical trial is studying proteomic profiling to see how well it works in diagnosing non-small cell lung cancer in patients who are undergoing resection for suspicious (abnormal) stage I lung lesions.

Clinical Trial Description

OBJECTIVES:

Primary

• Determine, prospectively, whether serum proteomic profiling can predict the presence of primary non-small cell lung cancer in patients with clinically suspicious stage I lung lesions who are undergoing lung resection.

Secondary

• Correlate the serum proteomic profile with pathologic nodal status and histopathologic features of primary lung cancer in these patients.

• Correlate the initial and follow-up serum proteomic profile with overall and cancer-specific survival of these patients.

• Correlate changes in the proteomic profile (preoperative to postoperative) with overall and cancer-specific survival of these patients.

Tertiary

• Determine whether novel molecular strategies can predict the presence of lung cancer and/or the biologic behavior of an individual cancer in these patients. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Lung Neoplasms

• NCT number: NCT00077324
• Study type: Observational
• Source: Alliance for Clinical Trials in Oncology
• Status: Completed
• Phase: N/A
• Start date: February 2004
• Completion date: November 2011